ClinicalTrials.gg
RecruitingNCT07138716Updated Aug 24, 2025

Research on the Application of 68Ga-DOTA-CCK-FS PET/CT in MTC

An interventional study of 68Ga-DOTA-CCK-FS PET/CT in Medullary Thyroid Carcinoma, sponsored by Luo Yaping. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2025-08-24.

Sponsored by Luo Yaping · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Carcinoma, Medullary with a site in China — 9 open to participants now, 11 under way, 2 of them phase 3. Carcinoma, Medullary · China.

Planned enrollment
13th of 16
30 · median 151
Started
2025
with 1 other
No phase
3 of 18
3 open now
Primary completion
2027-12
later than 9 of 10 live
Registered
15th of 18
by date
Lead sponsor
1 of 18
Luo Yaping

Among the 18 studies in Carcinoma, Medullary with a site in China, this one is the 13th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2025, is one of 3 with no phase, reaches primary completion later than 9 of the 10 other live ones, and was the 15th registered.

Carcinoma, Medullary

144 studies on the registry are indexed under Carcinoma, Medullary; 30 are open to participants now.

Browse Carcinoma, Medullary studies →

Open to participants now

9 of the 18 studies in Carcinoma, Medullary with a site in China are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 16 Carcinoma, Medullary studies recruiting now, 9 (56%) set no upper age limit and 3 (19%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Carcinoma, Medullary with a site in China, or all of them as a file.
02

Study summary

This study explores the clinical application of 68Ga-DOTA-CCK-FS PET/CT in detecting cholecystokinin-2 receptor (CCK-2R)-positive tumors, particularly medullary thyroid cancer (MTC) and other malignancies. Led by Prof. Luo Yaping (PUMCH Nuclear Medicine) and Prof. Liu Zhibo (Peking University, radiochemistry expert), the trial will enroll 30-40 patients to compare 68Ga-DOTA-CCK-FS imaging with standard PET/CT (e.g., 18F-FDG or 68Ga-DOTATATE). The novel tracer shows higher tumor uptake and retention in preclinical studies, potentially improving diagnosis and treatment guidance for aggressive, CCK-2R-expressing cancers. The study leverages PUMCH's Class IV Radioactive Drug License for advanced radiopharmaceutical development. Risks are minimal (diagnostic radiation dose only), and participants receive free imaging assessments. Results aim to refine precision diagnostics for MTC and related tumors.

Read the detailed description

This clinical study investigates the diagnostic potential of 68Ga-DOTA-CCK-FS PET/CT, a novel radiopharmaceutical targeting the cholecystokinin-2 receptor (CCK-2R), in patients with medullary thyroid carcinoma (MTC) and other CCK-2R-expressing tumors. The research is led by Prof. Luo Yaping, Chief Physician at Peking Union Medical College Hospital (PUMCH), in collaboration with Prof. Liu Zhibo, a radiochemistry expert from Peking University. The trial will enroll 30-40 eligible patients with confirmed or suspected MTC (based on histopathology, elevated calcitonin/CEA levels, or MEN2 family history) or other CCK-2R-positive malignancies. Each participant will undergo 68Ga-DOTA-CCK-FS PET/CT, with comparative imaging (either 18F-FDG PET/CT for non-neuroendocrine tumors or 68Ga-DOTATATE PET/CT for neuroendocrine tumors) performed within 2 weeks. The study focuses on evaluating the tracer's sensitivity, specificity, and tumor-targeting efficiency through both visual and quantitative analyses (e.g., SUV measurements). Preclinical data suggest 68Ga-DOTA-CCK-FS offers superior tumor uptake and retention compared to existing probes, potentially enabling earlier detection and better therapeutic stratification for MTC, which often presents with aggressive metastasis and limited treatment options. PUMCH's Class IV Radioactive Drug License allows in-house production of this investigational tracer, addressing unmet clinical needs. Safety monitoring includes tracking minor injection-site reactions or radiation exposure (equivalent to a standard abdominal CT). Participants benefit from free advanced imaging and contribute to refining precision diagnostics for CCK-2R-driven cancers. Results may pave the way for future theranostic applications (e.g., 177Lu-labeled CCK-2R therapy).

03

Conditions studied

  • Medullary Thyroid Carcinoma

Browse trials for

Keywords

  • MTC
  • CCK-2R
  • PET/CT
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age not limited (male or female).
  2. Diagnosis:Confirmed or suspected medullary thyroid carcinoma (MTC) based on:

    Fine-needle aspiration (FNA) cytology/histopathology, or Elevated serum calcitonin/CEA with thyroid nodule(s), or Clinical/hereditary suspicion (e.g., MEN2 syndrome), or Other confirmed CCK-2R-positive tumors (e.g., neuroendocrine tumors, gastric/ovarian cancers).

  3. Performance Status: ≥12 weeks.
  4. : Willingness to use effective birth control (if applicable).
  5. Consent: Signed and compliance with follow-up.

Exclusion criteria

Exclusion Criteria:

  1. Severe hepatic/renal dysfunction (e.g., /AST >3×, Cr >2.0 mg/dL).
  2. Pregnancy/lactation or planned pregnancy during the study.
  3. Inability to lie still for PET/CT (e.g., severe claustrophobia).
  4. Concurrent conditions compromising study safety (investigator's judgment).

*Note: CCK-2R positivity may be confirmed via prior immunohistochemistry (if available) or inferred from tumor type (e.g., MTC).*

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Other
    68Ga-DOTA-CCK-FS and 68Ga-DOTA-TATE PET/CT imaging

    For the patients with neuroendocrine neoplasm. Intravenous administration of 1.8-2.2 MBq/kg (0.05-0.06 mCi/kg) of each radiotracer within one week. For 68Ga-DOTA-CCK-FS, imaging begins 60±5 minutes post-injection to evaluate cholecystokinin receptor (CCK-R) expression, while 68Ga-DOTA-TATE scanning starts at 45-60 minutes post-injection for somatostatin receptor (SSTR) assessment, both using a time-of-flight PET/CT system with low-dose CT (120 kVp, 30-50 mAs) for attenuation correction followed by whole-body PET acquisition (2-3 min/bed position). Images are reconstructed using OSEM algorithms

    Diagnostic Test: 68Ga-DOTA-CCK-FS PET/CT

  • Other
    68Ga-DOTA-CCK-FS and 18F-FDG PET/CT imaging

    For the patients with non-neuroendocrine neoplasm. 68Ga-DOTA-CCK-FS PET/CT was perfomed 60±5 minutes post-injection of 1.8-2.2 MBq/kg (0.05-0.06 mCi/kg) tracer. The 18F-FDG PET/CT imaging protocol requires patients to fast for at least 6 hours and maintain blood glucose levels \<150-200 mg/dL prior to intravenous administration of 3.7-5.2 MBq/kg (0.1-0.14 mCi/kg) of 18F-FDG. After a 60±5 minute uptake period , imaging is performed on a time-of-flight PET/CT system (2-3 minutes per bed position, covering skull base to mid-thigh).

    Diagnostic Test: 68Ga-DOTA-CCK-FS PET/CT

Interventions

  • Diagnostic test68Ga-DOTA-CCK-FS PET/CT

    For 68Ga-DOTA-CCK-FS, imaging begins 60±5 minutes post-injection to evaluate cholecystokinin receptor (CCK-R) expression, using a time-of-flight PET/CT system with low-dose CT (120 kVp, 30-50 mAs) for attenuation correction followed by whole-body PET acquisition (2-3 min/bed position). Images are reconstructed using OSEM algorithms.

06

What researchers measure

Primary outcomes

  1. diagnostic performance

    Diagnostic performance of 68Ga-DOTA-CCK-FS PET/CT in detecting CCK-2R-positive tumors, as measured by sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy using histopathology or clinical follow-up as the reference standard.

    Time frame: through study completion, an average of 1 year

Secondary outcomes

  1. Comparative efficacy

    Comparative efficacy of 68Ga-DOTA-CCK-FS PET/CT versus standard imaging (18F-FDG PET/CT for non-neuroendocrine tumors or 68Ga-DOTATATE PET/CT for neuroendocrine tumors) in: Tumor detection rate (number and location of lesions) Target-to-background ratio (TBR) based on SUVmax (tumor vs. liver/blood pool/muscle)

    Time frame: through study completion, an average of 1 year

  2. Correlation

    Correlation between 68Ga-DOTA-CCK-FS uptake (SUVmax/SUVpeak) and Serum tumor markers (e.g., calcitonin, CEA for MTC); Tumor differentiation status (if histopathology is available)

    Time frame: through study completion, an average of 1 year

  3. Safety profile

    Safety profile of 68Ga-DOTA-CCK-FS, assessed by Incidence of adverse events (AEs) related to tracer administration and Radiation dosimetry estimates

    Time frame: through study completion, an average of 1 year

Other outcomes

  1. Exploratory Outcomes

    Potential utility of 68Ga-DOTA-CCK-FS PET/CT for: Staging/restaging of MTC and other CCK-2R-positive tumors Predicting eligibility for future peptide receptor radionuclide therapy (PRRT) Inter-reader agreement in image interpretation (kappa statistics)

    Time frame: through study completion, an average of 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Due to patient privacy regulations and institutional policies, individual participant data (IPD) from this study will not be publicly available. The data contain sensitive clinical and genetic information that could compromise participant confidentiality. Additionally, Chinese data protection laws and hospital ethical guidelines restrict the open sharing of identifiable medical data. However, aggregated results (e.g., group-level imaging findings, statistical analyses) will be published in peer-reviewed journals. Researchers may request limited, anonymized datasets for collaborative purposes, subject to approval by the Peking Union Medical College Hospital (PUMCH) Ethics Committee and compliance with data transfer agreements.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Dec 2027, 30 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2025
First posted
Aug 24, 2025
StartActual
May 10, 2025
Primary completionEst.
Dec 1, 2027
CompletionEst.
Dec 1, 2028
Last update
Aug 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07138716
Lead sponsor
Luo Yaping
Responsible party
Luo Yaping (Medical Doctor (M.D.), Chief Physician, Professor, Assistant Director, Peking Union Medical College Hospital) — Sponsor-investigator
First posted
Aug 24, 2025
Start date
May 10, 2025
Primary completion
Dec 1, 2027 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Aug 24, 2025

Study contacts

Yaping Luo, MD
Contact
luoyaping@live.com
86-010-69154716
Yaping LUO
principal investigator · Peking Union Medical College Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion